QA108 Phase II Study in Subjects With Intermediate Age-Related Macular Degeneration
Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
This is a phase 2, randomized, double-masked, placebo-controlled, multicenter study. To
evaluate the efficacy and safety of QA108 granules in the treatment of intermediate
age-related macular degeneration.